

1 **Title:** Placental PFAS concentrations are associated with perturbations of placental DNA methylation at
2 loci with important roles on cardiometabolic health.

3

4 **Authors and Affiliations:**

5 Todd M. Everson^{1,2,*}, Neha Sehgal¹, Dana Boyd Barr¹, Parinya Panuwet¹, Volha Yakimavets¹, Cynthia
6 Perez¹, Kartik Shankar³, Stephanie M. Eick^{1,2}, Kevin J. Pearson⁴, Aline Andres^{5,6}

- 7 1. Gangarosa Department of Environmental Health, Emory University Rollins School of Public
8 Health, Atlanta, GA, USA
9 2. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA,
10 USA
11 3. Department of Pediatrics, Section of Nutrition, University of Colorado School of Medicine,
12 Aurora, CO
13 4. Department of Pharmacology & Nutritional Sciences, University of Kentucky College of
14 Medicine
15 5. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR
16 6. Arkansas Children's Nutrition Center, Little Rock, AR

17 **Corresponding Author Contact Information:**

18 *Correspondence should be addressed to Todd M. Everson (Todd.M.Everson@Emory.edu), PhD,
19 Gangarosa Department of Environmental Health, Emory University Rollins School of Public Health,
20 1518 Clifton Road NE, Mailstop 1518-002-2BB, Atlanta, GA 30322; Phone: 404.727.8136; Fax:
21 404.727.8744

22 **Key Words:** epigenetics, DNA methylation, PFAS, placenta, prenatal

23

24

25

26 **Abstract:**

27 The placenta is crucial for fetal development, is affected by PFAS toxicity, and evidence is accumulating
28 that gestational PFAS perturb the epigenetic activity of the placenta. Gestational PFAS exposure is can
29 adversely affect offspring, yet individual and cumulative impacts of PFAS on the placental epigenome
30 remain underexplored. Here, we conducted an epigenome-wide association study (EWAS) to examine the
31 relationships between placental PFAS levels and DNA methylation in a cohort of mother-infant dyads in
32 Arkansas. We measured 17 PFAS in human placental tissues and quantified placental DNA methylation
33 levels via the Illumina EPIC Microarray. We tested for differential DNA methylation with individual
34 PFAS, and with mixtures of multiple PFAS. Our results demonstrated that numerous epigenetic loci were
35 perturbed by PFAS, with PFHxS exhibiting the most abundant effects. Mixture analyses suggested
36 cumulative effects of PFOA and PFOS, while PFHxS may act more independently. We additionally
37 explored whether sex-specific effects may be present and concluded that future large studies should
38 explicitly test for sex-specific effects. The genes that are annotated to our PFAS-associated epigenetic loci
39 are primarily involved in growth processes and cardiometabolic health, while some genes are involved in
40 neurodevelopment. These findings shed light on how prenatal PFAS exposures affect birth outcomes and
41 children's health, emphasizing the importance of understanding PFAS mechanisms in the in-utero
42 environment.

43

44 **Introduction:**

45 Per- and polyfluoroalkyl substances (PFAS) are man-made chemicals that are ubiquitously used
46 in consumer products, food packaging, and firefighting foams. These chemicals are of significant
47 environmental concerns due to their pervasiveness in everyday products and their persistence in the
48 environment and human biomatrices [1]. Human exposure to PFAS is linked to several health outcomes,
49 including multiple cardiometabolic conditions, and adverse effects during pregnancy (e.g., birth and
50 developmental outcomes) [2]. Several mechanisms could explain these intergenerational effects,
51 including direct fetal exposure from maternal circulation or by disrupting maternal physiology including
52 placental development and function. Some quantity of PFAS from maternal circulation pass through the
53 placenta to reach many fetal organ systems, and PFAS bioaccumulate in the placenta throughout gestation
54 [3]. PFAS accumulation in the placenta may have consequences on placental function and moderation of
55 the *in-utero* environment.

56 A recent review Szilagyi et al (2020) highlighted a likely role for PFAS interactions with
57 peroxisome proliferator-activated receptors (PPARs), which may impact placental functions [4]. PPARs
58 are nuclear receptors that broadly regulate lipid, hormone and glucose metabolism [5], and are associated
59 with placentation and trophoblast differentiation [4]. PPAR activities in the placenta serve many roles,
60 and influences the expression of multiple genes and pathways involved in placental development [6].
61 Additionally, epigenetic alterations, such as changes in DNA methylation, may impact placental function,
62 affect birth outcomes and children's health, since other persistent organic pollutants (POPs) have such
63 effects [7]. A few recent studies have begun to explore the impact of prenatal PFAS on the human
64 placental epigenome. Wang et al (2023) used a targeted gene approach and global methylation analysis, to
65 show that placental PFAS levels were negatively associated LINE-1 methylation and with CpGs in the
66 nuclear receptor subfamily 3 group C member 1 (*NR3C1*) gene; and that PFAS associations with
67 placental methylation and birth outcomes may be modified by sex [8]. An epigenome-wide association
68 study (EWAS) of several persistent organic pollutants in maternal plasma, including PFAS, found that
69 several individual PFAS were associated with differences in DNA methylation levels of 39 CpG sites [9].

70 Another study examined relationships between maternal plasma PFAS concentrations with placental
71 DNAm differences using reduced representation bisulfite sequencing in a sub-sample (n=16), then
72 demonstrated more statistically robust associations with three of these five candidates in the full cohort
73 (n=345) [10]. Thus, to date, studies of the impacts of gestational PFAS exposure on the human placental
74 methylome have primarily utilized maternal plasma as an exposure biomarker, or when placental PFAS
75 levels were quantified, they were only examined in association with targeted genes and features.

76 Given that the placenta is likely affected by PFAS toxicity, and individual PFAS have been
77 shown to be associated with DNA methylation differences in a handful of placental epigenomic studies,
78 there is a need to further characterize the cumulative impacts of PFAS in the placenta on the placental
79 epigenome. Such studies which better reflect real world PFAS exposure patterns can help to elucidate the
80 mechanisms by which PFAS exert their effects on placental function and the *in-utero* environment. Here,
81 we performed an EWAS of the relationships between placental PFAS concentrations with differences in
82 DNA methylation. We first examined these relationships for each individual PFAS compound that was
83 uniformly detected in our sample, then examined the associations with the overall mixture of PFAS on
84 DNA methylation, and last explored whether there was evidence of sex-specific effects.

85

86

87 **Methods:**

88 *Study Population*

89 This study was performed as part of the Glowing Study in Little Rock, Arkansas, which recruited
90 pregnant women prior to gestational week 10, and enrollment occurred between 2010 and 2014
91 (www.clinicaltrials.gov, ID #NCT03281850) [11, 12]. This longitudinal observational cohort consisted of
92 300 second parity dyads, from singleton pregnancies, with mothers who were at least 21 years of age.
93 Exclusion criteria included self-reported pre-existing medical conditions, sexually transmitted infections,
94 medical complications, reported smoking or alcohol use during pregnancy, or medication use during
95 pregnancy known to influence fetal growth (e.g. gestational diabetes, thyroid disease, pre-eclampsia) and
96 conceptions aided with fertility treatment. Infants included in the analyses had no medical conditions and
97 required no medications known to influence growth or development of the fetus. This study included all
98 dyads where placental samples were collected, and where PFAS and DNA methylation quantification
99 passed quality control (n=151). All study participants provided informed, written consent and the study
100 was approved by the University of Arkansas for Medical Sciences Institutional Review Board.

101 *Placental Collection and Processing*

102 Placentas were collected within 30 minutes of delivery and processed within 2 hours, those with
103 severe placental pathologies were excluded. Placental tissues from the villous core, maternal and fetal
104 sides were separately collected from 6 random sites (~1 sq. in) and washed thrice in ice-cold PBS to
105 remove maternal blood. Samples were then flash-frozen. For comprehensive representation of the entire
106 placenta, ~1 g of pooled tissue from all six collection sites (each compartment separately) was frozen in
107 liquid nitrogen and pulverized. Tissue samples were pooled from all regions of the villous core and the
108 same pooled pulverized sample was used for all -omics and PFAS analysis.

109 *Placental PFAS Quantification*

110 Placental samples were randomized prior to analysis to reduce analytical batch effects. Powdered
111 placental tissue (0.2-0.7mg per sample), was spiked with isotopically labeled analogues of target PFAS,
112 then homogenized in methanol. The 17 target PFAS include: perfluorohexanoic acid (PFHxA),

113 perfluorohexane sulfonic acid (PFHxS), perfluoroheptanoic acid (PFHpA), perfluorooctanoic acid
114 (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorooctane sulfonamide (PFOSA), n-
115 methylperfluoro-1-octanesulfonamidoacetic acid (MePFOSAA), perfluorononanoic acid (PFNA),
116 perfluorodecanoic acid (PFDA), perfluorodecane sulfonic acid (PFDS), perfluoroundecanoic acid
117 (PFUnDA), perfluorododecanoic acid (PFDoDA), perfluoropentanoic acid (PFPeA), n-ethylperfluoro-1-
118 octanesulfonamidoacetic acid (EtPFOSAA), hexafluoropropyleneoxide dimer acid (HFPO-DA; Gen X),
119 perfluoroheptane sulfonic acid (PFHpS), and perfluorobutanesulfonic acid (PFBS). The homogenized
120 samples were centrifuged, and the methanol layer was separated from the placenta tissue. The methanolic
121 fraction was then evaporated to almost dryness and mixed with a mixture of methanol: 0.1M formic acid
122 (40:60, v/v). The samples were introduced onto a Strata RP on-line extraction column (2.1 x 20 mm). The
123 on-line extraction column was washed with 0.1 M formic acid: acetonitrile (90:10, V/V). Then, the target
124 analytes were transferred to a Betasil C18 analytical column (6 x 150 mm) for chromatographic
125 separation. The target PFAS were analyzed using high-performance liquid chromatography-tandem mass
126 spectrometry (LC-MS/MS) with electrospray ionization. The analyte concentrations were calculated using
127 isotope dilution calibration. The unknown samples were analyzed alongside a replicate of solvent-based
128 blanks for background evaluation and quality control materials (2 levels) for precision and accuracy
129 assurance.

130 Two samples that had insufficient quantity of tissue to perform quantification were excluded from
131 further analyses, yielding a sample size of 151 for analyses of placental PFAS levels. Concentrations of
132 five PFAS (PFHxS, PFOS, PFOA, PFNA, and PFDA) were detectable in over 70% of placental samples.
133 All downstream analyses focused on these five PFAS. Concentrations below the limit of detection (LOD)
134 were imputed via $LOD/\sqrt{2}$ and data were natural log-transformed prior to performing statistical analyses.

135 *Placental DNA methylation Quantification*

136 DNA extraction was performed using PureLink Genomic DNA isolation reagents (Thermo
137 Fisher). DNA was quantified with Qubit dsDNA quantification assays (Thermo Fisher, Waltham, MA,
138 USA), then aliquoted into standardized concentrations to allow for a total mass of 500 ng of DNA.

139 Samples were randomly distributed across 96-well plates, rows, and chips to reduce the potential for
140 batch effects. The Emory University Integrated Genomics Core performed bisulfite conversion using the
141 EZ DNA Methylation Kit (Zymo Research, Irvine, CA) and measured DNAm throughout the genome
142 using the Illumina MethylationEPIC Beadarray (Illumina, San Diego, CA) following the manufacturer's
143 protocol. All 153 placental DNA samples passed quality control, with no samples yielding more than 1%
144 or of probes with detection p values > 0.05. Functional normalization [13] and beta-mixture quantile
145 (BMIQ) normalization were performed [14] to normalize technical differences on the arrays and correct
146 for different distributions between type-I and type-II probe designs. Then probes on the X and Y
147 chromosomes, those that had single nucleotide polymorphisms (SNP) within the binding region, and
148 those that could cross-hybridize to other regions of the genome [15] were excluded.

149 *Statistical Analyses*

150 All statistical analyses were performed in RStudio (version 4.3.0 or above). Frequencies and
151 arithmetic means and standard deviations (SDs) were used to describe the distribution of demographic
152 variables. Geometric means and SDs and selected percentiles were used to summarize PFAS
153 concentrations. Violin plots were used to visualize the distributions of natural log transformed PFAS.
154 Spearman correlation coefficients were used to determine the relation between each placental PFAS.

155 Prior to conducting the epigenome wide association study (EWAS), we performed two
156 unsupervised data reduction steps to reduce multiple testing burden and increase power. First, we utilized
157 CoMeBack to identify proximal CpG sites that exhibit highly correlated methylation patterns and
158 clustered these CpGs into co-methylated regions (CMRs) [16]. For each CMR, principal component
159 analysis was performed and the first component was used as a summary measure of the of DNAm within
160 each CMR. This step identified 57,146 CMRs representing the DNAm of 158,924 CpG sites. Many CpG
161 sites that were not clustered in CMRs and these were retained as individual CpG sites, for a total of
162 599,048 epigenetic loci (CpGs + CMRs). Next, since CpGs with low variability are more prone to be
163 affected by measurement error and may yield less reproducible findings [17], we excluded CpGs or

164 CMRs with low standard deviation ($SD < 0.02$). After performing these data reduction steps, 365,376
165 epigenetic loci were available for analyses – 49,470 CMRs and 315,906 individual CpGs.

166 We conducted five EWAS to characterize the relationships between DNAm levels and the
167 concentrations of five individual PFAS chemicals in placental tissue. We used robust linear regression
168 models from the MASS package which implement M-estimation with Huber and bisquare weighting to
169 reduce the influence of outliers [18], to regress DNA methylation beta values on natural log transformed
170 PFAS concentrations. All models were adjusted for technical covariates and potential confounders that
171 were determined *a priori* based on a directed acyclic graph (DAG, **Supplemental Figure S1**). All models
172 were adjusted for maternal BMI (normal weight, overweight/obesity), maternal age at delivery,
173 gestational age at birth, maternal educational attainment, infant sex, DNA methylation batch, and
174 proportions of placental cell types (trophoblasts, stromal cells, Hofbauer cells, endothelial cells, nRBCs,
175 and syncytiotrophoblasts), which were estimated via the *planet* package in R [19]. We evaluated genomic
176 inflation factors and QQ-plots for evidence of inflation and calculated false-discovery rate (FDR) for each
177 PFAS EWAS, considering those associations with FDR q-values < 0.05 as statistically significant.

178 We then used secondary analyses to evaluate whether there was a mixture effect on DNA
179 methylation from simultaneous exposure to multiple PFAS congeners in the placenta. For this, we
180 performed a targeted analysis of the CpGs that were significantly associated with any one of the PFAS
181 congeners from the primary EWAS. For these analyses we applied quantile g-computation, a parametric
182 generalized linear modelling approach that performs g-computation [20]. This method estimates the
183 overall effect of the placental PFAS mixture by simultaneously increasing all concentrations by one
184 quartile, while controlling for the same potential confounders and technical factors described above. In
185 addition to estimating the overall mixture effect, each PFAS component in the mixture is assigned a
186 partial positive or a partial negative weight, regardless of the direction and magnitude of the overall
187 mixture effect. All weights in the same direction sum to 1, indicating the relative contribution of an
188 individual PFAS towards that direction of effect on methylation for a given loci. Because the weights
189 represent relative contributions for only a particular direction of effect, the weights in a particular

190 direction should only be compared and be evaluated separately for each epigenetic loci. We performed
191 two quantile g-computation analysis to quantify the effect of placental PFAS exposure on each loci. In
192 our first approach, we did not allow for interaction between individual PFAS. In our second approach, we
193 allowed for the model to include all two-way interaction terms using bootstrapping.

194 Additionally, because emerging evidence suggests that developmental exposure to PFAS may
195 have sexually dimorphic effects on some outcomes [21], we explored whether there was any evidence of
196 sex-specific associations from the individual PFAS or from the PFAS mixture on DNAm. For these
197 analyses, we performed the untargeted EWAS for each of the 5 PFAS among females (N=63) and males
198 (N=88) separately. These models had the same covariate adjustments as above but did not include sex as
199 a covariate.

200 Last we performed functional enrichment analyses to test whether the sets of epigenetic loci that
201 we identified in our EWAS were components within broader biological processes or functions. We used
202 the *missMethyl* package in R to test for gene ontology (GO) term and Kyoto Encyclopedia of Genes and
203 Genomes (KEGG) pathway enrichment, since this method corrects for probe number bias [22].

204 **Results:**

205 *Study Population*

206 This study sample included mother-infant dyads from the Glowing Study for whom placental
207 DNAm and placental PFAS were quantified. As part of enrollment criteria, all mothers were self-reported
208 non-smokers and were second parity. The study sample (n=151) primarily represented healthy
209 pregnancies and birth outcomes (**Table 1**). The mean maternal age at the time of delivery was 30.5 years
210 (SD = 3.42 years) and most of the mothers had a college degree (66.9%) and self-identified as White
211 (86.1%). The 151 infants included 63 females and 88 males, who were born with an average gestation of
212 39.3 weeks (range 36.4 – 41.4 weeks).

213 *Placental PFAS Quantification*

214 Concentrations of five PFAS were detectable in over 70% of placental samples: PFHxS, PFOS,
215 PFOA, PFNA, and PFDA. As displayed in **Table 2**, PFOS was detected at the highest rate and had the
216 highest average concentrations, while PFOA and PFHxS had the second and third highest concentrations.
217 Data were natural log-transformed prior to downstream analyses to deal with the right skewed
218 distributions but some distributions for LOD-imputed PFAS remain non-normal (**Supplemental Figure**
219 **S2**). The placental concentrations of these PFAS were moderately correlated with each other
220 (**Supplemental Figure S3**), with the strongest pairwise correlation between PFNA and PFDA (Spearman
221 $\rho = 0.71$), the weakest correlation between PFHxS and PFDA or PFNA (Spearman $\rho = 0.30$), and
222 PFHxS generally exhibiting lower correlations with other PFAS.

223 *Epigenome-Wide Association Study (EWAS) of Placental PFAS*

224 We performed five EWAS, to estimate differences in DNA methylation across 365,376
225 epigenetic loci. Genomic inflation factors and QQ plots for each EWAS indicated minimal evidence of
226 inflation (**Supplemental Figure S4**). We identified differential methylation at 23 epigenetic loci (FDR q-
227 values < 0.05; **Figure 1**) with PFHxS having the greatest number of associations (11 loci), followed by
228 PFNA (5 loci), PFOS (4 loci), PFOA (2 loci), and PFDA (1 loci) (**Table 3**). While the loci that were
229 associated each of these five PFAS differed, the parameter estimates for their associations were very

230 highly correlated (**Supplemental Figure S5**). Parameter estimates for PFOS and PFNA exhibited the
231 strongest correlations (Spearman $\rho = 0.93$), while the parameter estimates for PFHxS with all other
232 PFAS were the weakest, but still moderate-to-strong correlations (ρ range 0.71 – 0.79). The overall
233 EWAS output will be made publicly available upon publication.

234 *Secondary PFAS Mixtures Analyses*

235 Since our findings above show that PFAS concentrations in the placenta were moderately
236 correlated with each other, and the 23 loci that were associated with any PFAS exhibited correlated
237 effects on DNAm, we hypothesized that PFAS may not have independent effects on DNAm but instead
238 may have synergistic or cumulative effects. Thus, we examined whether placental DNAm levels at these
239 23 loci were significantly impacted by simultaneous exposure to PFAS. Using quantile g-computation, we
240 found that overall, a simultaneous increase in all five PFAS by one quartile was associated with reduced
241 methylation levels at 6 loci and with increased methylation levels at 6 loci in the placental tissue (**Figure**
242 **2** and **Table S1**). Partial positive and negative weights from quantile g-computation show the proportion
243 of the effect in a particular direction associated with each PFAS. Some of the mixture results were similar
244 to the EWAS results for each PFAS, where PFHxS greatly contributed to the positive effects while PFOS,
245 PFOA, and PFNA primarily contributes to the negative direction (**Figure 3**).

246 However, multiple interesting findings emerged from the mixture analyses. For instance, PFOS
247 had a negative weight for all loci for which there was a significant negative mixture effect, but other
248 PFAS had stronger negative weights for each of these negative mixture effects. Additionally, PFOS was
249 assigned a positive weight for 4 of the 6 loci with significant positive mixture effects, but only had the
250 strongest weight for cg14603624. Similarly, the PFOA weights aligned with the overall mixture effects
251 for all of the significant mixture effects, except for cg15641477, where it had an opposite direction of
252 effect, and for cg10720382 where it was assigned a weight of zero. The other three PFAS had more
253 variation in their contributions to the significant mixture effects. Interestingly, among the loci with
254 significant mixture effects, only one exhibited the same direction of the weights for all five PFAS,
255 cg17718899. This locus was only significantly associated ($FDR < 0.05$) with high PFOA levels in the

256 individual EWAS models, but in the mixture model all five PFAS had positive weights, with the strongest
257 positive contributions coming from PFOA, PFHxS, and PFNA, respectively. For most loci, 1, 2, or 3
258 PFAS were driving the majority of the directional effects, and other PFAS weights were close to zero or
259 in the opposite direction of the mixture effect.

260 When we tested for interactions between each PFAS included in the mixture, we observed that, a
261 simultaneous increase in all five PFAS by one quartile was linked with reduced methylation at
262 cg20856960 and cg11442048 via potential interactions (**Supplementary Table S2**). Interestingly, both
263 quantile g-computation approaches suggested that methylation levels at cg11442048 (annotated to
264 LOC100128568 and *RFX2* genes on chr19) were reduced upon placental mixture PFAS exposure
265 suggesting that this may be an important target site for several PFAS.

266 *Sex-Specific Analyses*

267 We explored whether the effect of each individual PFAS on the placental methylome was differential
268 among males and females via stratified analyses (**Supplementary Figure S6 and Table S1**). We
269 observed that p-values tended to be smaller, effect sizes larger, and larger numbers of statistically
270 significant loci were identified in the sex-stratified models. Specifically, in sex stratified models, we
271 observed that increasing exposure to PFAS tended to be linked with substantially more methylation
272 perturbations among females than males. This was particularly apparent for PFHxS and PFOS levels,
273 which were associated with 644 and 232 loci respectively in females, and with 137 and 125 loci
274 respectively in males (FDR < 0.05).

275 *Functional Enrichment Analyses*

276 Last, we aimed to understand whether any GO terms or KEGG pathways were enriched among
277 the epigenetic loci that were most differentially methylated with increasing PFAS concentrations. Since
278 the 23 loci that yielded EWAS associations (FDR < 0.05) were only annotated to 10 genes, we expanded
279 our gene list to include any loci that yielded an EWAS association p-value < 1.0e-05, which included 103
280 loci. No GO terms were significantly enriched after adjusting for bias and multiple testing. One KEGG

281 pathway was significantly enriched (FDR q -value < 0.05), *Valine, leucine and isoleucine biosynthesis*
282 (hsa00290).

283

284

285 **Discussion:**

286 We quantified 17 PFAS concentrations in placental tissue from the Glowing cohort of mother-
287 infant dyads in the Central Arkansas region. We show that several placental PFAS concentrations are
288 associated with differential DNAm at several epigenetic loci. In our study, placental PFAS concentrations
289 were moderately correlated with each other. We found that PFHxS exhibited the largest number of
290 significant differentially methylated epigenetic loci. When we compared parameter estimates across
291 EWAS, while still correlated for multiple pairwise comparisons, the parameter estimates for PFHxS had
292 the weakest correlations with the parameter estimates for all other PFAS. Our secondary analyses with
293 mixture modeling revealed that 12 of the 23 tested sites exhibited significant mixture effects and that
294 PFOS and PFOA generally contributed to mixture effects in the same direction, whereas the other three
295 PFAS were more variable in their contributions to mixture effects. Additionally in the mixture analyses,
296 PFHxS was assigned strong weights in opposite directions of other PFAS for many of our identified loci.
297 These findings could suggest that PFOS and PFOA may have more synergistic or cumulative impact on
298 the placental methylome and that PFHxS has a more unique effect on the placental epigenome compared
299 to the other 4 PFAS that we tested. Notably, PFHxS has been a common replacement for PFOS and
300 PFOA, under the assumption that shorter chain PFAS may be less toxic than legacy PFAS [23]. PFHxS
301 was also very highly detected in the ground water at an air force base north of Little Rock, AR [24]. Thus,
302 the potential impacts of prenatal PFAS exposure, and particularly PFHxS, are important for this and
303 similarly exposed populations.

304 The vast majority of epidemiologic studies have examined concentrations of PFAS in maternal
305 samples, while only a handful have quantified placental PFAS concentrations, which may be more
306 reflective of direct *in utero* exposure. We compared our placental PFAS levels to one other published
307 study from a US cohort, where PFAS were quantified in placenta sampled between 2010 – 2011 in
308 Durham, North Carolina. Complimentary to our findings, Hall et al. (2022) observed similar average
309 placental concentrations of 4 PFAS, a similar correlation structure among these PFAS, and that PFOS had
310 highest concentrations [25]. While Hall et al. did not examine placental epigenetic responses, they did

311 find that increasing concentrations of placental PFAS were associated with smaller birth size for
312 gestational age and that there may be some sex-specific effects on fetal growth [25].

313 Interestingly, several of the genes and epigenetic loci that we identified as differentially
314 methylated in association with increasing placental PFAS concentrations have been associated with other
315 endocrine disrupting chemicals and with cardiometabolic outcomes. For instance, multiple CpGs within
316 *XKR6*, among other CpGs and genes, were found to have lower DNA methylation levels among placenta
317 of newborns with selective fetal growth restriction [26]. Higher levels of maternal urinary bisphenol A
318 (BPA) concentrations were associated with lower DNA methylation of one CpG in *XKR6* [27].
319 Additionally, maternal glucose concentrations during early pregnancy were associated with differences in
320 DNA methylation at one CpG in *XKR6* [28]. Placental DNA methylation levels of CpGs in *NAV2* have
321 previously been associated with maternal systolic blood pressure [29, 30]. The expression of *KCNQ3* was
322 shown to be upregulated in placentas from mother with preeclampsia [31]. Notably, *Early B Cell*
323 *Transcription Factor 1 (EBF1)*, annotated to cg14572446, has been associated with multiple traits
324 (GWAS catalog [32]), including anthropometrics, body composition, and lipid profiles, and CpGs
325 annotated to *EBF1* were also identified in the only other placental PFAS-EWAS to date [9]. Interestingly,
326 in our study, DNAm of cg14572446 within *EBF1* was positively related to simultaneous increase in both
327 PFHxS and PFOA. *In-vitro* experiments showed that Bisphenol S (BPS) was associated with decreased
328 expression of *MESP2* in preadipocytes [33]. While our functional enrichment analyses only yielded one
329 significantly enriched KEGG pathway – *valine, leucine and isoleucine biosynthesis*, it is of note that
330 several untargeted metabolomics studies of PFAS have identified this same pathway being perturbed with
331 PFAS exposure [34]. Prenatal exposure to PFAS has been associated with non-alcoholic fatty liver
332 disease in children, and perturbations to valine, leucine, isoleucine metabolism and biosynthesis, along
333 with other amino acids and lipids, were identified as potential intermediaries [35, 36]. In another study,
334 maternal plasma concentrations of PFAS were associated with perturbations to multiple amino acid
335 metabolism and biosynthesis pathways, with leucine, isoleucine, valine metabolism exhibiting the
336 greatest number of associations [37]. Circulating levels of valine, leucine, and isoleucine are also

337 important predictors or biomarkers of several cardiometabolic diseases [38]. Overall, many of the genes
338 annotated to our PFAS-associated epigenetic loci serve important roles in cardiometabolic health, and
339 some of these have been shown to be affected by other endocrine disrupting chemicals.

340 In addition to cardiometabolic health, some of these genes are important in neurodevelopment. In
341 a rat model, prenatal BPA exposure was associated with altered expression of *KCNQ3* in the amygdala of
342 exposed females [39], and *KCNQ3* may have important functions in some neurodevelopmental outcomes
343 [40]. *NAV2* guides axonal outgrowth and plays critical roles in early cerebellar development [41], while
344 *PLEKHG2* is also involved in axonal growth, and impaired function is likely involved in neuronal
345 disorders [42]. Importantly, our study did not examine whether DNAm at our PFAS-associated epigenetic
346 loci was associated with the expression of the genes or metabolites that we describe above. Additionally,
347 many genes have pleiotropic effects with roles in numerous biological processes and phenotypes. The
348 actual genomic and phenotypic consequences of our observed differential DNAm are not clear, but these
349 prior studies provide important context about the biological process and potential phenotypic outcomes
350 that may be involved in such responses to prenatal PFAS exposures.

351 Our study contributes to the emerging evidence that PFAS impact the epigenetic regulation of the
352 placenta and these findings may have implications for cardiometabolic health or other children's health
353 outcomes. Importantly, our study utilized placental PFAS concentrations to study the impacts on the
354 placental methylome, allowing for a more proximal exposure biomarker that may also be highly impactful
355 on the *in-utero* environment. However, there are several limitations of this work that should be considered
356 when interpreting our findings. While we utilized two data reduction steps to improve power and applied
357 an FDR correction to identify significant differential DNAm, our sample size was modest for an
358 epigenome wide approach (n=151). This moderate sample size also resulted in reduced statistical power,
359 particularly in the sex-stratified analyses. However, our sex-stratified analyses are hypothesis-generating,
360 and suggest that future studies of placental PFAS and DNAm should explicitly plan for and perform
361 analyses to identify sex-specific effects. Additionally, the Glowing Cohort represents a healthy population
362 in central Arkansas. While this reduces potential generalizability to other populations, our study also

363 represents an important contribution to the characterization of risk factors for adverse child growth and
364 cardiometabolic health in a population that has potentially high exposure to some PFAS and high rates of
365 low birthweight. Despite some limitations, our study provides a substantial contribution towards
366 understanding the placental epigenetic responses to PFAS.

367

368 **Conclusions**

369 We performed an EWAS of placental PFAS levels associated with placental DNAm in a healthy
370 cohort of mother-infant dyads from Arkansas. We found that numerous epigenetic loci in the placenta
371 appear to be perturbed in association with increasing PFAS concentrations, and that PFHxS had the most
372 pronounced effect in this study. Mixture analyses revealed that PFOA and PFOS tended to have
373 consistent directions and possibly cumulative effects on several epigenetic loci, while PFHxS tended to
374 perturb the placental methylome more independently. Additionally, we provide suggestive evidence that
375 sex-specific associations are an important consideration for future studies. The genes that are annotated to
376 our identified loci predominantly play important roles in growth and cardiometabolic health, but we also
377 identified several genes that are important in neurodevelopment. These findings can provide insights into
378 the mechanisms through which prenatal PFAS exposures impact birth outcomes and children's health.
379

380 **CRedit authorship contribution statement**

381 **Todd M Everson:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology,
382 Writing – original draft, Writing – review & editing. **Neha Sehgal:** Formal analysis, Methodology,
383 Visualization, Writing – original draft, Writing – review & editing. **Dana Boyd Barr:** Data curation,
384 Methodology, Writing – review & editing. **Parinya Panuwet:** Formal analysis. **Volha Yakimavets:**
385 Formal analysis. **Cynthia Perez:** Formal Analysis. **Stephanie M. Eick:** Methodology, Writing – review
386 & editing. **Karitk Shankar:** Formal Analysis, Methodology, Data Curation, Writing – review & editing.
387 **Kevin J Pearson:** Funding Acquisition, Project administration, Writing – review & editing. **Aline**
388 **Andres:** Data Curation, Program Administration, Funding acquisition, Writing – review & editing.

389

390 **Declaration of competing interest**

391 The authors declare that they have no known competing financial interests or personal relationships that
392 could have appeared to influence the work reported in this paper.

393

394 **Acknowledgments**

395 We acknowledge all the families who chose to participate in this study as well as the Arkansas Children's
396 Nutrition Center team for the data and samples acquisition for the Glowing Study.

397

398 **Funding statement**

399 This work was supported by funding from the National Institute of Environmental Health Sciences,
400 NIH/NIEHS [R01 ES032176; MPIs: Andres, Everson, & Pearson], the HERCULES Center [P30
401 ES019776; Everson, Barr, Eick] and the USDA-ARS [6026-51000-012-06S; Glowing cohort].

402 Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the
403 views NIH.

404

405 **Data availability**

406 Raw and processed epigenetic data will be made available on NCBI GEO upon publication.

407

409 **References:**

410

- 411 1. Evich MG, Davis MJB, McCord JP, Acrey B, Awkerman JA, Knappe DRU, Lindstrom AB, Speth TF, Tebes-Stevens C,
412 Strynar MJ *et al*: **Per- and polyfluoroalkyl substances in the environment**. *Science* 2022, **375**(6580):eabg9065.
- 413 2. Fenton SE, Ducatman A, Boobis A, DeWitt JC, Lau C, Ng C, Smith JS, Roberts SM: **Per- and Polyfluoroalkyl**
414 **Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing**
415 **Future Research**. *Environ Toxicol Chem* 2021, **40**(3):606-630.
- 416 3. Mamsen LS, Bjorvang RD, Mucs D, Vinnars MT, Papadogiannakis N, Lindh CH, Andersen CY, Damdimopoulou P:
417 **Concentrations of perfluoroalkyl substances (PFASs) in human embryonic and fetal organs from first, second,**
418 **and third trimester pregnancies**. *Environ Int* 2019, **124**:482-492.
- 419 4. Szilagyi JT, Avula V, Fry RC: **Perfluoroalkyl Substances (PFAS) and Their Effects on the Placenta, Pregnancy, and**
420 **Child Development: a Potential Mechanistic Role for Placental Peroxisome Proliferator-Activated Receptors**
421 **(PPARs)**. *Current environmental health reports* 2020, **7**(3):222-230.
- 422 5. Evans N, Conley JM, Cardon M, Hartig P, Medlock-Kakaley E, Gray LE, Jr.: **In vitro activity of a panel of per- and**
423 **polyfluoroalkyl substances (PFAS), fatty acids, and pharmaceuticals in peroxisome proliferator-activated**
424 **receptor (PPAR) alpha, PPAR gamma, and estrogen receptor assays**. *Toxicology and applied pharmacology*
425 2022, **449**:116136.
- 426 6. Matsuda S, Kobayashi M, Kitagishi Y: **Expression and Function of PPARs in Placenta**. *PPAR Res* 2013,
427 **2013**:256508.
- 428 7. Lapehn S, Paquette AG: **The Placental Epigenome as a Molecular Link Between Prenatal Exposures and Fetal**
429 **Health Outcomes Through the DOHaD Hypothesis**. *Curr Environ Health Rep* 2022, **9**(3):490-501.
- 430 8. Wang H, Li W, Yang J, Wang Y, Du H, Han M, Xu L, Liu S, Yi J, Chen Y *et al*: **Gestational exposure to perfluoroalkyl**
431 **substances is associated with placental DNA methylation and birth size**. *Sci Total Environ* 2023, **858**(Pt
432 1):159747.
- 433 9. Ouidir M, Mendola P, Buck Louis GM, Kannan K, Zhang C, Tekola-Ayele F: **Concentrations of persistent organic**
434 **pollutants in maternal plasma and epigenome-wide placental DNA methylation**. *Clin Epigenetics* 2020,
435 **12**(1):103.
- 436 10. Xie Z, Sun S, Ji H, Miao M, He W, Song X, Cao W, Wu Q, Liang H, Yuan W: **Prenatal exposure to per- and**
437 **polyfluoroalkyl substances and DNA methylation in the placenta: A prospective cohort study**. *J Hazard Mater*
438 2024, **463**:132845.
- 439 11. Diaz EC, Williams DK, Howie EK, Borsheim E, Andres A: **Offspring sex modifies the association between early-**
440 **pregnancy adiposity and 2-year-old physical activity-The Glowing Study**. *Int J Obes (Lond)* 2024, **48**(4):542-549.
- 441 12. Heard-Lipsmeyer ME, Diaz EC, Sims CR, Sobik SR, Ruebel ML, Thakali KM, Krukowski RA, Cleves M, Borsheim E,
442 Shankar K, Andres A: **Maternal Adiposity is Associated with Fat Mass Accretion in Female but not Male**
443 **Offspring During the First 2 Years of Life**. *Obesity* 2020, **28**(3):624-630.
- 444 13. Fortin JP, Triche TJ, Jr., Hansen KD: **Preprocessing, normalization and integration of the Illumina**
445 **HumanMethylationEPIC array with minfi**. *Bioinformatics (Oxford, England)* 2017, **33**(4):558-560.
- 446 14. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S: **A beta-mixture quantile**
447 **normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data**.
448 *Bioinformatics* 2013, **29**(2):189-196.
- 449 15. Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, Van Dijk S, Muhlhäusler B, Stirzaker C,
450 Clark SJ: **Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA**
451 **methylation profiling**. *Genome biology* 2016, **17**(1):208.
- 452 16. Gatev E, Gladish N, Mostafavi S, Kobor MS: **CoMeBack: DNA methylation array data analysis for co-methylated**
453 **regions**. *Bioinformatics* 2020, **36**(9):2675-2683.
- 454 17. Logue MW, Smith AK, Wolf EJ, Maniates H, Stone A, Schichman SA, McGlinchey RE, Milberg W, Miller MW: **The**
455 **correlation of methylation levels measured using Illumina 450K and EPIC BeadChips in blood samples**.
456 *Epigenomics* 2017, **9**(11):1363-1371.
- 457 18. Venables WN, Ripley BD: **Modern applied statistics with S**, Fourth Edition edn: Springer; 2002.
- 458 19. Yuan V, Hui D, Yin Y, Penaherrera MS, Beristain AG, Robinson WP: **Cell-specific characterization of the placental**
459 **methylome**. *BMC Genomics* 2021, **22**(1):6.

- 460 20. Keil AP, Buckley JP, O'Brien KM, Ferguson KK, Zhao S, White AJ: **A Quantile-Based g-Computation Approach to**
461 **Addressing the Effects of Exposure Mixtures.** *Environmental health perspectives* 2020, **128**(4):47004.
- 462 21. Svoboda LK, Ishikawa T, Dolinoy DC: **Developmental toxicant exposures and sex-specific effects on epigenetic**
463 **programming and cardiovascular health across generations.** *Environ Epigenet* 2022, **8**(1):dvac017.
- 464 22. Phipson B, Maksimovic J, Oshlack A: **missMethyl: an R package for analyzing data from Illumina's**
465 **HumanMethylation450 platform.** *Bioinformatics (Oxford, England)* 2016, **32**(2):286-288.
- 466 23. Ateia M, Maroli A, Tharayil N, Karanfil T: **The overlooked short- and ultrashort-chain poly- and perfluorinated**
467 **substances: A review.** *Chemosphere* 2019, **220**:866-882.
- 468 24. **PFAS Contamination in the U.S. (February 5, 2024)** [[https://www.ewg.org/interactive-](https://www.ewg.org/interactive-maps/pfas_contamination/map/)
469 [maps/pfas_contamination/map/](https://www.ewg.org/interactive-maps/pfas_contamination/map/)]
- 470 25. Hall SM, Zhang S, Hoffman K, Miranda ML, Stapleton HM: **Concentrations of per- and polyfluoroalkyl**
471 **substances (PFAS) in human placental tissues and associations with birth outcomes.** *Chemosphere* 2022,
472 **295**:133873.
- 473 26. Shi D, Zhou X, Cai L, Wei X, Zhang L, Sun Q, Zhou F, Sun L: **Placental DNA methylation analysis of selective fetal**
474 **growth restriction in monochorionic twins reveals aberrant methylated CYP11A1 gene for fetal growth**
475 **restriction.** *FASEB J* 2023, **37**(10):e23207.
- 476 27. McCabe CF, Padmanabhan V, Dolinoy DC, Domino SE, Jones TR, Bakulski KM, Goodrich JM: **Maternal**
477 **environmental exposure to bisphenols and epigenome-wide DNA methylation in infant cord blood.** *Environ*
478 *Epigenet* 2020, **6**(1):dvaa021.
- 479 28. Geurtsen ML, Jaddoe VWV, Gaillard R, Felix JF: **Associations of maternal early-pregnancy blood glucose and**
480 **insulin concentrations with DNA methylation in newborns.** *Clin Epigenetics* 2020, **12**(1):134.
- 481 29. Broseus L, Vaiman D, Tost J, Martin CRS, Jacobi M, Schwartz JD, Beranger R, Slama R, Heude B, Lepeule J:
482 **Maternal blood pressure associates with placental DNA methylation both directly and through alterations in**
483 **cell-type composition.** *BMC Med* 2022, **20**(1):397.
- 484 30. Workalemahu T, Ouidir M, Shrestha D, Wu J, Grantz KL, Tekola-Ayele F: **Differential DNA Methylation in**
485 **Placenta Associated With Maternal Blood Pressure During Pregnancy.** *Hypertension* 2020, **75**(4):1117-1124.
- 486 31. Mistry HD, McCallum LA, Kurlak LO, Greenwood IA, Broughton Pipkin F, Tribe RM: **Novel expression and**
487 **regulation of voltage-dependent potassium channels in placentas from women with preeclampsia.**
488 *Hypertension* 2011, **58**(3):497-504.
- 489 32. Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, Groza T, Gunes O, Hall P, Hayhurst J *et al*: **The NHGRI-EBI**
490 **GWAS Catalog: knowledgebase and deposition resource.** *Nucleic acids research* 2023, **51**(D1):D977-D985.
- 491 33. Boucher JG, Gagne R, Rowan-Carroll A, Boudreau A, Yauk CL, Atlas E: **Bisphenol A and Bisphenol S Induce**
492 **Distinct Transcriptional Profiles in Differentiating Human Primary Preadipocytes.** *PloS one* 2016,
493 **11**(9):e0163318.
- 494 34. India-Aldana S, Yao M, Midya V, Colicino E, Chatzi L, Chu J, Gennings C, Jones DP, Loos RJF, Setiawan VW *et al*:
495 **PFAS Exposures and the Human Metabolome: A Systematic Review of Epidemiological Studies.** *Curr Pollut Rep*
496 2023, **9**(3):510-568.
- 497 35. Jin R, McConnell R, Catherine C, Xu S, Walker DI, Stratakis N, Jones DP, Miller GW, Peng C, Conti DV *et al*:
498 **Perfluoroalkyl substances and severity of nonalcoholic fatty liver in Children: An untargeted metabolomics**
499 **approach.** *Environ Int* 2020, **134**:105220.
- 500 36. Stratakis N, D VC, Jin R, Margetaki K, Valvi D, Siskos AP, Maitre L, Garcia E, Varo N, Zhao Y *et al*: **Prenatal**
501 **Exposure to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver Injury in Children.**
502 *Hepatology* 2020, **72**(5):1758-1770.
- 503 37. Prince N, Begum S, Minguez-Alarcon L, Genard-Walton M, Huang M, Soeteman DI, Wheelock C, Litonjua AA,
504 Weiss ST, Kelly RS, Lasky-Su J: **Plasma concentrations of per- and polyfluoroalkyl substances are associated**
505 **with perturbations in lipid and amino acid metabolism.** *Chemosphere* 2023, **324**:138228.
- 506 38. Fine KS, Wilkins JT, Sawicki KT: **Circulating Branched Chain Amino Acids and Cardiometabolic Disease.** *J Am*
507 *Heart Assoc* 2024, **13**(7):e031617.
- 508 39. Arambula SE, Jima D, Patisaul HB: **Prenatal bisphenol A (BPA) exposure alters the transcriptome of the neonate**
509 **rat amygdala in a sex-specific manner: a CLARITY-BPA consortium study.** *Neurotoxicology* 2018, **65**:207-220.
- 510 40. Sands TT, Miceli F, Lesca G, Beck AE, Sadleir LG, Arrington DK, Schonewolf-Greulich B, Moutton S, Lauritano A,
511 Nappi P *et al*: **Autism and developmental disability caused by KCNQ3 gain-of-function variants.** *Ann Neurol*
512 2019, **86**(2):181-192.

- 513 41. Accogli A, Lu S, Musante I, Scudieri P, Rosenfeld JA, Severino M, Baldassari S, Iacomino M, Riva A, Balagura G *et*
514 *al*: **Loss of Neuron Navigator 2 Impairs Brain and Cerebellar Development.** *Cerebellum* 2023, **22**(2):206-222.
515 42. Nishikawa M, Ito H, Tabata H, Ueda H, Nagata KI: **Impaired Function of PLEKHG2, a Rho-Guanine Nucleotide-**
516 **Exchange Factor, Disrupts Corticogenesis in Neurodevelopmental Phenotypes.** *Cells* 2022, **11**(4).

517

518

519

520 **Tables and Figures for “Placental PFAS concentrations associated with perturbations of placental DNA**
521 **methylation”.**

522

523

524

Table 1: Distribution of demographic variables in the Glowing study, 2010-2014.

	Overall (N=151)
Infant Sex	
Female	63 (41.7%)
Male	88 (58.3%)
BMI Enrollment Category	
Pregnant women with normal weight	74 (49.0%)
Pregnancy women with overweight or obesity	77 (51.0%)
Maternal Race	
White	130 (86.1%)
Non-White	21 (13.9%)
Maternal Educational Attainment	
College Degree	101 (66.9%)
No College Degree	50 (33.11%)
Maternal Age at Delivery (years)	
Mean (SD)	30.5 (3.42)
Median [Min, Max]	30.2 [22.5, 42.4]
Gestational Age at Birth (weeks)	
Mean (SD)	39.3 (0.85)
Median [Min, Max]	39.3 [36.4, 41.4]

525

526

527
528

Table 2: Distribution of placental per- and polyfluoroalkyl substances levels (ng/g) in the Glowing study, 2010-2014.

	Above Limit of Detection (%)	N	Geometric Mean	Geometric Standard Deviation	Percentiles				
					5%	25%	50%	75%	95%
PFHxS	83.4	151	0.05	2.82	0.01	0.04	0.05	0.08	0.23
PFOA	74.8	151	0.05	2.87	0.01	0.01	0.07	0.11	0.24
PFNA	98.0	151	0.05	1.86	0.02	0.03	0.05	0.08	0.12
PFOS	98.7	151	0.38	2.01	0.12	0.26	0.43	0.58	0.97
PFDA	68.9	151	0.025	2.48	0.01	0.01	0.04	0.05	0.07

529
530
531

532
533
534
535
536

Table 3: Placental EWAS results for PFOS, PFOA, PFHxS, PFDA, and PFNA, for the 23 loci that were associated with at least one PFAS; Beta represents the estimated differential methylation with a 1-ln increase in PFAS and bold text is used to highlight those associations that yielded FDR q-values (q-val.) < 0.05; Loci that were CMRs list multiple CpG IDs.

Epigenetic Loci	PFOS		PFOA		PFHxS		PFDA		PFNA	
	Beta	q-val.	Beta	q-val.	Beta	q-val.	Beta	q-val.	Beta	q-val.
cg01793178	0.0211	0.03	0.0049	1.00	0.0108	0.22	-0.0007	0.99	0.0138	1.00
cg15438999	-0.0136	0.04	-0.0072	0.94	-0.0037	0.85	-0.0111	0.31	-0.0154	0.80
cg24634055	0.0218	0.04	0.0016	1.00	0.0048	0.86	0.0074	0.83	0.0048	1.00
cg14603624	0.0323	0.04	0.0063	1.00	0.0102	0.76	0.0123	0.79	0.0216	1.00
cg18434560	-0.0122	0.18	-0.0097	0.03	-0.0070	0.33	-0.0039	0.85	-0.0107	0.89
cg17718899	0.0082	0.38	0.0067	0.03	0.0051	0.46	0.0035	0.82	0.0081	0.61
cg00011173	-0.0111	0.46	-0.0046	1.00	0.0011	0.96	-0.0064	0.69	-0.0180	0.03
cg24371331	-0.0082	0.77	-0.0048	0.99	-0.0006	0.97	-0.0073	0.38	-0.0132	0.05
cg15641477	-0.0253	0.54	-0.0086	1.00	-0.0083	0.82	-0.0186	0.46	-0.0393	0.02
cg20856960; cg22399868	-0.0095	1.00	-0.0043	1.00	-0.0014	0.96	-0.0073	0.68	-0.0191	0.05
cg13318071; cg18107425	-0.0077	0.10	-0.0022	1.00	-0.0032	0.61	-0.0033	0.75	-0.0096	0.02
cg11442048	-0.0052	1.00	-0.0064	0.99	-0.0032	0.83	-0.0116	0.02	-0.0080	1.00
cg08889114	0.0029	1.00	0.0060	1.00	0.0119	0.04	0.0023	0.97	-0.0001	1.00
cg21845400	-0.0002	1.00	0.0036	1.00	0.0148	0.02	-0.0004	1.00	-0.0020	1.00
cg09786142	0.0122	0.66	0.0113	0.55	0.0130	0.03	0.0056	0.89	0.0074	1.00
cg22420548	0.0070	1.00	0.0059	1.00	0.0159	0.02	0.0034	0.96	0.0079	1.00
cg14572446	0.0155	1.00	0.0116	1.00	0.0303	0.04	0.0091	0.90	0.0079	1.00
cg14434870	0.0077	1.00	-0.0005	1.00	0.0134	0.04	0.0032	0.96	-0.0010	1.00
cg04962865	0.0319	0.99	0.0175	1.00	0.0325	0.04	0.0083	0.95	0.0221	1.00
cg26670786	0.0090	1.00	0.0052	1.00	0.0138	0.01	0.0022	0.97	0.0050	1.00
cg10720382	0.0053	1.00	0.0042	1.00	0.0084	0.03	0.0024	0.93	0.0039	1.00
cg22921147	0.0105	1.00	0.0020	1.00	0.0153	0.01	-0.0002	1.00	0.0037	1.00
cg21880197	-0.0045	1.00	-0.0026	1.00	-0.0103	0.04	-0.0027	0.95	-0.0037	1.00

537
538
539
540


541
542

Table 4: Genomic annotations for 23 CpGs associated with any of PFOS, PFOA, PFHxS, PFDA, or PFNA.

Epigenetic loci	Gene	Chromosome
cg01793178	Intergenic	chr1
cg15438999	Intergenic	chr2
cg24634055	<i>XKR6</i>	chr8
cg14603624	Intergenic	chr9
cg18434560	Intergenic	chr11
cg17718899	Intergenic	chr13
cg00011173	Intergenic	chr18
cg24371331	<i>PLEKHG2</i>	chr19
cg15641477	<i>DDRGI1</i>	chr20
cg20856960	<i>NAV2</i>	chr11
cg13318071	<i>MESP2</i>	chr15
cg11442048	LOC100128568; <i>RFX2</i>	chr19
cg08889114	Intergenic	chr3
cg21845400	Intergenic	chr4
cg09786142	LINC01511	chr5
cg22420548	Intergenic	chr5
cg14572446	<i>EBF1</i>	chr5
cg14434870	Intergenic	chr6
cg04962865	Intergenic	chr8
cg26670786	<i>KCNQ3</i>	chr8
cg10720382	Intergenic	chr9
cg22921147	Intergenic	chr12
cg21880197	Intergenic	chr14


543
544
545

Figure 1: Volcano plot for the associations between increasing concentrations of placental per- and polyfluoroalkyl substances (PFAS) levels with placental DNA methylation levels for the 23 CpGs that were significantly impacted by any one of the five PFAS in the Glowing study (N=151), 2010-2014.




Note: All models adjusted for maternal BMI (normal weight or overweight/obesity), maternal age at delivery, gestational age at birth, maternal educational attainment, infant sex, DNA methylation batch, and proportions of placental cell types (trophoblasts, stromal cells, Hofbauer cells, endothelial cells, nRBCs, and syncytiotrophoblasts). Increased or reduced methylation is based on whether the association was above or below 0, respectively and the FDR q -values < 0.05 .

Figure 2: Volcano plots for the mixture effect of placental per- and polyfluoroalkyl substances (PFAS in ng/g) exposure on placental DNA methylation levels of the 23 CpGs that were significantly impacted by any one of the five PFAS, overall (N=151) in the Glowing study, 2010-2014.



Note: All models adjusted for maternal BMI (normal weight versus overweight/obesity), maternal age at delivery, gestational age at birth, maternal educational attainment, infant sex, DNA methylation batch, and proportions of placental cell types (trophoblasts, stromal cells, Hofbauer cells, endothelial cells, nRBCs, and syncytiotrophoblasts). Increased or reduced methylation is based on whether the association was above or below 0, respectively and the p-values < 0.05.

Figure 3: Positive and negative weights showing the partial effects of placental per- and polyfluoroalkyl substances (PFAS in ng/g) on individual placental DNA methylation levels of the 23 CpGs that were significantly impacted by any one of the five PFAS in linear regression models, estimated using quantile g-computation, overall (N=151) in the Glowing study, 2010-2014.



Note: Shown are the partial plots from the quantile g-computation for the 23 loci that were statistically significantly (i.e., FDR q-values < 0.05) associated with any one of the PFAS EWAS. Epigenetic loci are ordered (on the y-axis) by largest to smallest mixture effect estimate of quantile g-computation and are bolded if the mixture effect was statistically significant (p < 0.05) and the y-axis is grouped based on whether the overall mixture effect of PFAS on the methylation levels of a particular loci was positive (i.e., increased methylation; orange) or negative (i.e., reduced methylation; purple). Within each row, the purple hued boxes show the negative weights whereas, the brown-orange hued boxes show the positive weights. All negative weights in a row together sum to 1 whereas, all positive weights in a row sum to 1. The weights correspond to the effect size relative to other's effects in the same direction and should not be directly compared across loci. All models adjusted for maternal BMI (normal weight versus overweight/obesity), maternal age at delivery, gestational age at birth, maternal educational attainment, infant sex, DNA methylation batch, and proportions of placental cell types (trophoblasts, stromal cells, Hofbauer cells, endothelial cells, nRBCs, and syncytiotrophoblasts)